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Abstract Accumulation of the DNA/RNA binding pro-
tein fused in sarcoma (FUS) as inclusions in neurons and
glia is the pathological hallmark of amyotrophic lateral
sclerosis patients with mutations in FUS (ALS-FUS) as well
as in several subtypes of frontotemporal lobar degeneration
(FTLD-FUS), which are not associated with FUS muta-
tions. Despite some overlap in the phenotype and
neuropathology of FTLD-FUS and ALS-FUS, significant
differences of potential pathomechanistic relevance were
recently identified in the protein composition of inclusions
in these conditions. While ALS-FUS showed only accu-
mulation of FUS, inclusions in FTLD-FUS revealed co-
accumulation of all members of the FET protein family, that
include FUS, Ewing’s sarcoma (EWS) and TATA-binding
protein-associated factor 15 (TAF15) suggesting a more
complex disturbance of transportin-mediated nuclear
import of proteins in FTLD-FUS compared to ALS-FUS.
To gain more insight into the mechanisms of inclusion body
formation, we investigated the role of Transportin 1 (Trn1)
as well as 13 additional cargo proteins of Transportin in the
spectrum of FUS-opathies by immunohistochemistry and
biochemically. FUS-positive inclusions in six ALS-FUS
cases including four different mutations did not label for
Trn1. In sharp contrast, the FET-positive pathology in all
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FTLD-FUS subtypes was also strongly labeled for Trn1 and
often associated with a reduction in the normal nuclear
staining of Trn1 in inclusion bearing cells, while no bio-
chemical changes of Trn1 were detectable in FTLD-FUS.
Notably, despite the dramatic changes in the subcellular
distribution of Trn1 in FTLD-FUS, alterations of its cargo
proteins were restricted to FET proteins and no changes in
the normal physiological staining of 13 additional Trn1
targets, such as hnRNPA1, PAPBN1 and Sam68, were
observed in FTLD-FUS. These data imply a specific dys-
function in the interaction between Trn1 and FET proteins
in the inclusion body formation in FTLD-FUS. Moreover,
the absence of Trn1 in ALS-FUS provides further evidence
that ALS-FUS and FTLD-FUS have different underlying
pathomechanisms.
Keywords Transportin  FUS  TAF15  EWS 
Amyotrophic lateral sclerosis  Frontotemporal dementia
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal
lobar degeneration (FTLD) are clinically, genetically and
neuropathologically heterogeneous groups of neurodegen-
erative diseases. The neuropathology is characterized by
the abnormal intracellular accumulation of specific proteins
with the accumulation of the fused in sarcoma protein
(FUS, also known as translocated in liposarcoma, TLS)
being the characteristic lesion in *3 % of ALS cases and
*10 % of FTLD cases, subsumed as FTLD-FUS [20].
FUS is a multifunctional DNA/RNA binding protein
and belongs to the FET family of proteins that also
includes Ewing’s sarcoma (EWS) protein, TATA-binding
protein-associated factor 15 (TAF15) and the drosophila
orthologue Cabeza [14, 17]. The FET proteins are pre-
dominantly nuclear, ubiquitously expressed, highly
conserved proteins with predicted roles in RNA tran-
scription, processing, transport, microRNA processing and
DNA repair [14, 17, 34]. All of the FET proteins are
shuttling proteins [12, 39, 40] and their nuclear import is
mediated by a non-classical nuclear localization signal,
called PY-NLS, recognized by the nuclear import protein
Transportin 1 (Trn1) [7, 18].
ALS cases with FUS pathology are almost always
associated with a mutation in the FUS gene (ALS-FUS).
Mutations in the gene FUS were first identified in 2009 as
the cause of familial ALS type 6 [15, 37] and then rapidly
confirmed in large ALS cohorts accounting for *3 % of
familial and \1 % of sporadic ALS [20]. The neuropa-
thology of ALS-FUS is characterized by abnormal
cytoplasmic inclusions in neurons and glia that are
immunoreactive for FUS [3, 9, 10, 15, 29, 37]. Significant
pathological heterogeneity with respect to morphological
and regional distribution of FUS pathology has been
described in ALS-FUS allowing delineation of two distinct
patterns correlating with disease severity and specific
mutations [23]. The majority of FUS mutations cluster in
the C terminus of the protein which includes its PY-NLS.
They have been shown to disrupt the PY-NLS motif
leading to impaired Trn1-mediated nuclear import of FUS
and subsequent increase of cytoplasmic FUS levels [7, 11,
13]. Notably, the level of nuclear import impairment that
results from specific FUS mutations in cultured cells
directly correlates with the clinical phenotype and the
neuropathological patterns observed in ALS-FUS, thereby
strongly suggesting that altered nuclear import of FUS is a
key event in the pathogenesis of ALS-FUS.
FTLD-FUS includes three distinct clinico-pathological
entities; atypical FTLD-U (aFTLD-U), basophilic inclusion
body disease (BIBD) and neuronal intermediate filament
inclusion disease (NIFID) [19, 24–26]. FTLD-FUS is
mostly associated with sporadic early onset of behavioral
variant of frontotemporal dementia with the exception of
single cases with positive family history [16, 25, 26, 31, 32,
36]. While possibly other genetic factors might be involved
in FTLD-FUS, in contrast to pure ALS with FUS pathology
which is usually associated with FUS mutations, no genetic
abnormalities of FUS have been identified in FTLD-FUS,
and the mechanisms underlying inclusion body formation
in FTLD-FUS remain unknown.
Although there is some clinical and pathological overlap
between ALS-FUS and FTLD-FUS, the presence of sig-
nificant differences in the genetics, phenotypes and the
morphological patterns of FUS pathology [21] raised the
question as to whether these conditions represent closely
related conditions with a shared pathomechanism or whe-
ther the pathogenic pathways triggered by FUS mutations
may be different from those involved in FTLD-FUS.
Indeed, the analysis of the FUS homologues TAF15 and
EWS has recently identified striking differences in the
protein composition of inclusions in these conditions, with
co-accumulation of all FET proteins in FTLD-FUS and
restricted accumulation of only FUS in ALS-FUS [27].
These data provided strong evidence for different patho-
logical processes underlying inclusion body formation and
cell death between ALS-FUS and FTLD-FUS, with ALS-
FUS being restricted to dysfunction of FUS, while FTLD-
FUS seems to be associated with a broader and more
complex dysregulation of Trn1-mediated nuclear import
affecting all FET proteins and perhaps other Trn1 cargos.
In the present study, we extend our immunohistochem-
ical analysis of the protein composition of inclusion bodies
in the spectrum of FUS-opathies to Trn1 and 13 additional
known Trn1 cargo proteins with a similar PY-NLS motif as
FET proteins.
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Methods
Case selection
The FUS-opathy cases included aFTLD-U (n = 17), BIBD
(n = 8), NIFID (n = 4) and six ALS cases with four dif-
ferent FUS mutations. Most of these cases have been
described in detail in previous studies [21, 23–27] and brief
clinical and demographic features are summarized in
Supplementary Table 1.
The original set of neurological control cases included
FTLD-TDP (n = 6; two with subtype A (one with GRN
mutation), two with subtype B (one with C9ORF72 muta-
tion) and two with subtype C [22]), FTLD-tau (n = 6; two
Pick’s disease, two corticobasal degeneration, and two pro-
gressive supranuclear palsy), FTLD with CHMP2B
mutations (n = 2), FTLD-ni (n = 3), sporadic ALS with
TDP pathology (n = 2), familial ALS with SOD1 mutations
(n = 2), Alzheimer’s disease (n = 2), dementia with Lewy
bodies (n = 2), Parkinson’s disease (n = 2), multiple sys-
tem atrophy (n = 2), Huntington’s disease (n = 2),
spinocerebellar ataxia (n = 3; one SCA-1 and two SCA-3)
and neuronal intranuclear inclusion body disease (n = 1).
When it was found that rare classical Lewy bodies in the
substantia nigra of the cases of Parkinson’s disease showed
some Trn1 immunoreactivity, the following additional
controls were added: sections of midbrain from six addi-
tional cases of Parkinson’s disease, sections of hippocampus
from two additional cases of dementia with Lewy bodies (to
check if immunoreactivity was restricted to Lewy bodies in
the substantia nigra) and sections of midbrain from three
additional cases of PSP (to check if immunoreactivity was
generalized to all types of cytoplasmic inclusions in nigral
neurons). Normal control tissue (n = 4) was from elderly
patients with no history of neurological disease.
Staining protocols for the 13 antibodies against other
PY-NLS proteins (Table 3) were established using a tissue
microarray including biopsy material from a glioblastoma
and a brain metastasis of a colon carcinoma as well as
postmortem tissue from the dentate granule cell layer and
temporal cortex of three controls with no history of neu-
rological disease.
Antibodies
A mouse monoclonal antibody was used for Trn1 immu-
nohistochemistry (IHC) (clone 45, Abcam, 1:200). All
FUS-opathy cases were stained for FUS (using either the
polyclonal anti-FUS HPA008784, Sigma-Aldrich, 1:2,000
or the monoclonal anti-FUS, ProteintechGroup, 1:1,000),
TAF15 using the polyclonal anti-TAF15 IHC-00094-1
(Bethyl Laboratories, 1:200), and EWS (using the mono-
clonal anti-EWS clone G5, Santa Cruz, 1:200, or the
polyclonal anti-EWS IHC-00086, Bethyl Laboratories,
1:200). The list of antibodies against 13 other Trn1 cargo
proteins with a PY-NLS investigated in this study is pro-
vided in Table 3.
Immunohistochemistry and double-label
immunofluorescence
Trn1 IHC was performed on 5-lm thick sections of for-
malin-fixed paraffin-embedded tissue for all FUS-opathy
and control cases on selected neuroanatomical regions
known to have robust pathology using the Ventana
BenchMark XT automated staining system (Ventana,
Tuscon, AZ) following microwave antigen retrieval and
developed with aminoethylcarbizole (AEC) or using the
NovoLinkTM Polymer Detection Kit and developed with
DAB. Staining with antibodies against other PY-NLS
Table 1 Summary of Trn1 and FET protein immunoreactivity in the spectrum of FUS-opathies
Diagnosis Number of cases (n) Immunohistochemical profile of inclusions
Trn1 FUS TAF15 EWS
FTLD-FUS
aFTLD-U 17 pos pos pos pos
BIBD 8 pos pos pos pos
NIFID 4 pos pos pos pos
ALS-FUS
p.R521C 2 neg pos neg neg
p.P525L 2 neg pos neg neg
p.R514S/E516V 1 neg pos neg neg
p.Q519lfsX9 1 neg pos neg neg
aFTLD-U atypical frontotemporal lobar degeneration with ubiquitinated inclusions, ALS-FUS amyotrophic lateral sclerosis with FUS mutation,
BIBD basophilic inclusion body disease, NIFID neuronal intermediate filament inclusion disease, pos positive, neg negative
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proteins was performed on selected cases with severe FUS
pathology (BIBD n = 1, aFTLD-U n = 4).
Incubation with primary antibodies was 32 min using
the automated staining system or 1 h for non-automated
staining procedure.
Double-label immunofluorescence (IF) was performed
on selected cases for FUS, TAF15, EWS and Trn1 or FUS
and other Trn1 substrates (Table 3). The secondary anti-
bodies were Alexa Fluor 594 and Alexa Fluor
488-conjugated anti-mouse and anti-rabbit IgG (Invitrogen,
1:500). 40-6-Diamidino-2-phenylindol (DAPI) was used for
nuclear counterstaining. IF images were obtained by wide-
field fluorescence microscopy (BX61 Olympus with digital
camera F-view, Olympus).
Biochemical analysis
Fresh-frozen postmortem frontal grey matter from aFTLD-
U (n = 5), BIBD (n = 1), NIFID (n = 1), FTLD with
TDP-43 pathology (n = 5), and normal controls (n = 4)
was used for the sequential extraction of proteins with
buffers of increasing stringency, using an established pro-
tocol [25, 27]. Briefly, gray matter was extracted at 2 ml/g
(v/w) by repeated homogenization and centrifugation steps
(120,0009g, 30 min, 4 C) with high-salt buffer (50 mM
Tris–HCl, 750 mM NaCl, 10 mM NaF, 5 mM EDTA, pH
7.4), 1 % Triton-X 100 in HS buffer, radioimmunopre-
cipitation assay buffer [50 mM Tris–HCl, 150 mM NaCl,
5 mM EDTA, 1 % NP-40, 0.5 % sodium deoxycholate,
0.1 % sodium dodecyl sulfate (SDS)] and 2 % SDS buffer.
To prevent carry over, each extraction step was performed
twice. Only supernatants from the first extraction steps
were analyzed while supernatants from the second wash
steps were discarded. The 2 %-SDS insoluble pellet was
extracted in 70 % formic acid at 0.5 ml/g (v/w), evaporated
in a SpeedVac system and the dried pellet was resuspended
in sample buffer and the pH was adjusted with NaOH.
Protease inhibitors were added to all buffers prior to use.
For immunoblot analysis, equal volumes of fractions from
different samples (10 ll of high-salt and TX, 20 ll of
RIPA and SDS, 25 ll of formic acid) were resolved by
7.5 % SDS-polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene difluoride membranes (Millipore,
Billerica, MA, USA). Following transfer, membranes were
blocked with Tris buffered saline containing 3 % powdered
milk and probed with the mouse monoclonal anti-Trn1
antibody (clone 45, Abcam, 1:500) or polyclonal anti-FUS
antibody (300-302A, Bethyl Laboratories, 1:10,000).
Primary antibodies were detected with horseradish per-
oxidase-conjugated anti-rabbit or anti-mouse IgG (Jackson
ImmunoResearch Europe, UK), signals were visualized by
a chemiluminescent reaction (Millipore) and the Chemi-
luminescence Imager Stella 3200 (Raytest, Switzerland).
Results
Trn1 co-aggregates with FET proteins in all FTLD-FUS
subtypes
Although there was some variation among cases and
anatomical regions, the normal physiological staining
pattern for Trn1 usually consisted of moderate to strong
Table 2 Immunoreactivity for Trn1 in other neurodegenerative
diseases
Diagnosis Regions examined Trn1
immunoreactivity
in signature lesions
AD Frontal cortex,
hippocampus
0/2
FTLD-TDP Frontal cortex,
hippocampus
0/6
FTLD with CHMP2B Hippocampus 0/2
FTLD-tau (PSP) Cerebellum, basal
ganglia, midbrain
0/5a
FTLD-tau (CBD) Basal ganglia 0/2
FTLD-tau (PiD) Hippocampus 0/2
FTLD-ni Hippocampus 0/3
ALS-TDP Spinal cord 0/3
ALS with SOD1 Spinal cord 0/2
MSA Pons, midbrain 0/2b
DLB Hippocampus 0/4
PD Midbrain 7/8c
SCA Pons 0/3
HD Basal ganglia 0/2
NIIBD Hippocampus 0/1
AD Alzheimer’s disease, ALS-SOD1 amyotrophic lateral sclerosis
with mutations in SOD1 gene, ALS-TDP amyotrophic lateral sclerosis
with TDP-43 pathology, CBD corticobasal degeneration, DLB
dementia with Lewy bodies, FTLD with CHMP2B frontotemporal
lobar degeneration with mutations in CHMP2B gene, FTLD-ni
frontotemporal lobar degeneration with no inclusions, FTLD-tau
frontotemporal lobar degeneration with tau pathology, FTLD-TDP
frontotemporal lobar degeneration with TDP-43 pathology, HD
Huntington’s disease, MSA multiple system atrophy, NIIBD neuronal
intranuclear inclusion body disease, PD Parkinson’s disease, PiD
Pick’s disease, PSP progressive supranuclear palsy, SCA spinocere-
bellar ataxia
a Trn1 staining of coarse cytoplasmic granules in substantia nigra
neurons, but no labeling of neurofibrillary tangles
b Trn1 staining of neuromelanin in substantia nigra neurons, but no
labeling of glial cytoplasmic inclusions
c In addition to weak labeling of a small number (*2–14 %) of
Lewy bodies in the substantia nigra in seven cases, all cases showed
labeling of coarse cytoplasmic granules in substantia nigra neurons
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immunoreactivity of nuclei and weak diffuse cytoplasmic
immunoreactivity in neurons (Fig. 1a).
In all subtypes of FTLD-FUS, Trn1 IHC revealed strong
labeling of neuronal and glial inclusions (Table 1; Fig. 1b–
g) with the frequency and morphology of inclusions being
comparable to those demonstrated with FUS and TAF15
IHC. Antibodies against EWS labeled fewer inclusions,
particularly in aFTLD-U, as previously described [27].
Specifically, aFTLD-U cases showed strong Trn1 staining
of neuronal cytoplasmic inclusions (NCI) and neuronal
intranuclear inclusions (NII) in the hippocampal dentate
fascia (Fig. 1b, c) and the frontotemporal cortex. The
numerous NCI in cortical, subcortical, brainstem and spinal
cord regions in NIFID (Fig. 1d, g) and BIBD (Fig. 1e)
cases were also strongly immunoreactive for Trn1. In
addition to NCI, FTLD-FUS cases showed variable num-
bers of Trn1-positive glial cytoplasmic inclusions (GCI;
Fig. 1f). The variability of physiological Trn1 immunore-
activity among cases mainly influenced by the time of
tissue fixation did not allow a detailed quantification, but in
cases with robust staining, inclusion bearing cells some-
times showed a clear reduction in nuclear Trn1 staining
compared to cells without inclusions (Supplementary
Fig. 1).
To confirm co-accumulation of Trn1 in the characteristic
inclusions in FTLD-FUS with all FET proteins, we
performed double-label immunohistochemistry for Trn1
and FUS, TAF15 or EWS of selected cases. This demon-
strated consistent co-labeling of all Trn1-positive NCI and
NII in cortical and spinal cord sections in aFTLD-U, NIFID
and BIBD for FUS (Fig. 2a–c), and TAF15 (Supplemen-
tary Fig. 2). EWS and Trn1 co-localized in all inclusions in
BIBD and NIFID cases, while in aFTLD-U only a subset
of Trn1-positive inclusions was EWS immunoreactive
(Supplementary Fig. 3).
Absence of Trn1 in inclusions in ALS with FUS
mutations
Trn1 staining was investigated in six ALS-FUS cases with
four different FUS mutations. All had previously been
shown to have robust FUS-positive (but TAF15- and EWS-
negative) pathology, particularly in the spinal cord and
motor cortex, that included NCI and variable numbers of
GCI [23]. In striking contrast to FTLD-FUS, no Trn1
immunoreactive neuronal or glial inclusions were detect-
able in cortical, subcortical, or spinal cord regions in any of
the ALS-FUS cases, while the physiological nuclear
staining pattern for Trn1 was retained (Fig. 1h). The
absence of Trn1 accumulation in FUS-positive NCI and
GCI in ALS-FUS was further confirmed by double-label IF
(Fig. 3a–c).
Table 3 Trn1 cargo proteins with PY-NLS investigated in FTLD-FUS
Protein name Antibody Physiological
staining pattern
Inclusions in
FTLD-FUS
Company Dilution Type
FUS ProteinTech Group (60160-1-Ig) 1:1,000 MM nucl pos
Sigma (HPA008784) 1:2,000 RP nucl pos
TAF15 Bethyl Laboratories (IHC-00094-1) 1:200 RP nucl pos
EWS Santa Cruz (clone G5) 1:200 MM nucl [ cyto pos
Bethyl Laboratories (IHC-00086) 1:200 RP nucl [ cyto pos
hnRNP A1 Santa Cruz (clone 4B10) 1:500 MM nucl neg
hnRNP A0 Abcam (ab66661) 1:100 RP nucl neg
hnRNP A2/B1 Sigma-Aldrich (clone DP3B3) 1:500 MM nucl neg
hnRNP M3/M4 Santa Cruz (clone 2A6) 1:250 MM nucl neg
hnRNP D ProteinTech Group (12770-1-AP) 1:500 RP nucl neg
hnRNP H1 ProteinTech Group (14774-1-AP) 1:50 RP nucl [ cyto neg
PQBP-1 ProteinTech Group (16264-1-AP) 1:250 RP nucl neg
SAM68 ProteinTech Group (10222-1-AP) 1:250 RP nucl neg
SLM-2 ProteinTech Group (13563-1-AP) 1:50 RP nucl neg
HEXIM1 ProteinTech Group (15676-1-AP) 1:50 RP nucl neg
RBM39 ProteinTech Group (21339-1-AP) 1:50 RP nucl [ cyto neg
HuR Santa Cruz (clone 3A2) 1:250 MM nucl neg
PABPN1 Abcam (EP3000Y) 1:1,000 RM nucl neg
Cyto cytoplasmatic, MM mouse monoclonal, nucl nuclear, pos positive, RP rabbit polyclonal, RM rabbit monoclonal, neg negative
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Trn1 staining in neurological controls
The normal and neurological control cases did not reveal
Trn1 immunoreactive pathology with one exception
(Table 2). Specifically, there was no labeling of the char-
acteristic inclusions in AD, FTLD-tau, FTLD-TDP, ALS-
TDP, ALS-SOD1, and MSA. The exception was weak
labeling of a subset of classical Lewy bodies in the sub-
stantia nigra in 7 of 8 PD cases with a frequency ranging
from 2 to 14 %. Notably, NII in SCA, HD and NIIBD,
which have previously been shown to be consistently FUS
positive and more variably EWS positive [6, 27, 38], were
negative for Trn1; a finding which further underlines the
specificity of FET and Trn1 immunoreactive inclusions in
FTLD-FUS.
Biochemical analysis of Trn1 in FTLD-FUS
To investigate potential biochemical alterations of Trn1
which might explain its co-accumulation in FTLD-FUS,
proteins were sequentially extracted from frozen brain tissue
from FTLD-FUS, as well as normal and neurological con-
trols, using the same extraction protocol previously used to
demonstrate changes in the solubility of FET protein as
consistent biochemical alteration in FTLD-FUS [25, 27, 28].
Trn1 could be detected as major band at the expected
molecular mass of *97 kDa, in the HS, Triton-X, RIPA
and SDS fractions in FTLD-FUS, as well as controls but
not in the formic acid fraction enriched for highly insoluble
Fig. 1 Trn1 immunohistochemistry in controls, FTLD-FUS and
ALS-FUS. The physiological staining pattern of Trn1 consists of
moderate to strong immunoreactivity of neuronal nuclei and weak
diffuse cytoplasmic staining as shown in control cortex (a). Abundant
Trn1-positive pathology is present in all affected brain regions in
FTLD-FUS cases (b–g), including neuronal cytoplasmic inclusions
(NCI) in the hippocampus in aFTLD-U (b, c), the neocortex (d) and
spinal cord (g) in NIFID and the pons in BIBD (e). In addition to NCI,
round and vermiform neuronal intranuclear inclusions (NII) were
labeled in cases of aFTLD-U and NIFID (arrows in c) and glial
cytoplasmic inclusions were present in the cerebral white matter (f).
In striking contrast to FTLD-FUS, no Trn1 positive pathology was
seen in ALS-FUS cases as shown for the spinal cord of the p.[R514S/
;E516V] mutation (h); note the absence of Trn1 immunoreactivity of
the basophilic inclusion (arrowhead in h) while nuclear staining is
retained (arrow in h). Scale bar 125 lm (a), 63 lm (b, e, h), 20 lm
(c), 90 lm (d, g), 45 lm (f)
b
Fig. 2 Co-localization of Trn1
and FUS in all FTLD-FUS
subtypes. Double-label
immunofluorescence for FUS
(red) and Trn1 (green), with
DAPI staining of nuclei in the
merged images. FUS-positive
inclusions in all FTLD-FUS
subtypes consistently showed
co-localization of FUS and
Trn1, as shown for neuronal
cytoplasmic inclusions (NCI)
and neuronal intranuclear
inclusions (NII, arrow in a) in
the dentate granule cells in
aFTLD-U (a), NCI in the
temporal cortex of NIFID
(b) and NCI and glial
cytoplasmic inclusions in the
spinal cord of BIBD (c). Scale
bar 10 lm
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proteins (Fig. 4). There was some variability in the signal
intensities between the different fractions among the vari-
ous cases and controls; however, no consistent changes
such as a shift in Trn1 solubility or additional Trn1 iso-
forms were observed in FTLD-FUS compared to controls.
As positive control and validation of the extraction proto-
col, the same protein fractions were analyzed by
immunoblot for FUS (Fig. 4), demonstrating a clear shift of
FUS from the soluble HS fraction towards the insoluble
SDS fraction in all FTLD-FUS cases compared to control
cases, in accordance with previous reports.
Absence of other PY-NLS proteins in inclusions
in FTLD-FUS
The co-accumulation of all FET proteins together with
Trn1 in FTLD-FUS suggests a complex impairment of
Trn1-mediated nuclear import in FTLD-FUS pathogene-
sis, raising the possibility that besides FET proteins other
Trn1 cargo proteins might also be affected in FTLD-
FUS. In order to test this hypothesis, we performed an
immunohistochemical analysis of FTLD-FUS cases for
13 additional PY-NLS proteins (Table 3) described as
validated cargo proteins of Trn1 [8, 18, 33]. IHC for all
showed a predominantly nuclear staining pattern that was
robust in neurons and weaker in glial cells in controls as
well as FTLD-FUS cases. However, none of the anti-
bodies against the additional PY-NLS proteins labeled
inclusions in FTLD-FUS and no change in their normal
physiological nuclear staining was observed in inclusion
bearing cells. The absence of labeling of inclusions was
confirmed by double-label immunofluorescence as illus-
trated for hnRNP A1, the best-characterized substrate
of Trn1 (Fig. 5a), SAM68 (Fig. 5b), and PABPN1
(Fig. 5c).
Discussion
FUS accumulation characterizes all cases of ALS with FUS
mutations and a variety of FTLD subtypes, collectively
referred to as FTLD-FUS [15, 19, 24–26, 37]; however, the
mechanisms of neurodegeneration in FUS-opathies are
only poorly understood.
Fig. 3 Absence of Trn1
pathology in ALS-FUS.
Double-label immuno-
fluorescence for FUS (red) and
Trn1 (green), with DAPI
staining of nuclei in the merged
images. FUS-positive inclusions
in ALS-FUS were not labeled
for Trn1 as shown for neuronal
cytoplasmic inclusions in the
spinal cord for three different
FUS mutations (a–c). Note the
physiological nuclear staining
for Trn1 in inclusion bearing
cells. FUS-positive glial
cytoplasmic inclusions present
in a subset of ALS-FUS cases
also showed no co-labeling for
Trn1 (arrow in a). Scale bar
10 lm
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Based on our recent findings on differences in the pro-
tein composition of inclusions between ALS-FUS and
FTLD-FUS with respect to the co-accumulation of the FUS
homologues EWS and TAF15 [27], the hypothesis has
emerged that these conditions might have different under-
lying pathomechanisms. The abnormality in ALS-FUS is
restricted to alterations and dysfunction of FUS that result
from FUS mutations that disrupt its PY-NLS and thereby
interfere with proper binding to its nuclear transport
receptor Trn1 and consecutive cytoplasmic accumulation
of FUS, but not TAF15 and EWS [7, 27]. In contrast,
FTLD-FUS is associated with accumulation of all FET
proteins, thereby suggesting a broader defect of nuclear
import pathways [5, 27], although the mechanism(s) of
FET accumulation in the absence of mutations in their PY-
NLS remain unclear.
Data presented in this study provide further strong evi-
dence for different underlying mechanisms of inclusion
body formation in ALS-FUS and FTLD-FUS by expanding
the differences in the protein composition of inclusions
between ALS-FUS and FTLD-FUS to Trn1.
None of the six ALS-FUS cases investigated (including
three different FUS missense and one truncation muta-
tions) showed alterations in the physiological staining
pattern of Trn1 or evidence for co-accumulation of Trn1
in the FUS-positive neuronal and glial inclusions. Thus,
the impaired binding capability of FUS with a mutated
PY-NLS to Trn1 [7] is not associated with detectable
changes in the subcellular distribution of Trn1 by IHC,
which is also reflected by the unaffected nuclear import of
other Trn1 cargo proteins such as TAF15 and EWS in
ALS-FUS [27]. Thus, the absence of Trn1 pathology in
ALS-FUS is consistent with the hypothesis that the
pathological processes underlying ALS-FUS are restricted
to dysfunctions of FUS.
In striking contrast to ALS-FUS, we demonstrate robust
and consistent co-accumulation of Trn1 with all FET pro-
teins in the various types of inclusions (NCI, GCI and NII)
in our large collection of FTLD-FUS cases, including 17
aFTLD-U, 8 BIBD and 4 NIFID cases, in accordance with
previous reports in smaller series of FTLD-FUS [4, 5].
Accumulation of Trn1 into cytoplasmic inclusions was
Fig. 4 Biochemical analysis of Trn1 and FUS in FTLD-FUS.
Proteins were sequentially extracted from frontal cortex of aFTLD-
U, NIFID, BIBD, controls without neurodegenerative disease as well
as FTLD-TDP as neurological controls. High-salt (fraction 1), Triton-
X-100 (fraction 2), RIPA (fraction 3), 2 % SDS (fraction 4) and
formic acid (fraction 5) protein fractions were separated by SDS-
PAGE and immunoblotted. Trn1 was present as one major band at the
expected molecular size for the full-length protein (*97 kDa) in
fractions 1–4 in FTLD-FUS and controls and was absent in fraction 5
enriched for highly insoluble proteins. While there was some
variability among signal intensities in the different fractions among
cases, no clear correlation of a distinct pattern was detectable in
FTLD-FUS compared to controls. For validation of protein extrac-
tions, samples were analyzed by anti-FUS immunoblot,
demonstrating full-length FUS at a molecular size of *73 kDa with
the amount of FUS present in the SDS fraction (fraction 4) being
much higher in FTLD-FUS cases compared to controls, in accordance
with previous reports
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often associated with a reduction in the physiological
nuclear staining of Trn1 in FTLD-FUS. Notably, the co-
labeling of inclusions for Trn1 and all FET proteins was
found to be a highly specific and unique feature of all
subtypes of FTLD-FUS that was not present in any of our
neurological controls, including those (HD, SCA, NIIBD)
characterized by FUS and variable EWS immunoreactive
NII [6, 27, 38]. These findings support the concept that
aFTLD-U, NIFID and BIBD are closely related disease
entities sharing the same pathomechanism [21]. Interest-
ingly, a small subset of LBs in the midbrain of PD cases
was found to be weakly positive for Trn1; however, the
significance of this finding needs further investigation.
The dramatic changes in the subcellular distribution of
Trn1 together with the accumulation of all FET proteins in
FTLD-FUS support the idea of a complex dysregulation of
Trn1-associated nuclear import in FTLD-FUS. This could
result from a primary defect of Trn1 itself, either by
posttranslational modifications, genetic variations or
altered expression levels. In this scenario, one might expect
to see changes of other Trn1 substrates and/or biochemical
alterations Trn1 itself.
However, our immunohistochemical analysis of a large
series of additional Trn1 cargo proteins failed to demon-
strate any abnormal accumulation or alterations in their
subcellular distribution. The Trn1 cargo proteins with PY-
NLS motifs similar to FET proteins included in this study
have all been validated in vitro as Trn1 binding proteins and
included hnRNP A1, the best studied Trn1 cargo [8, 18, 33].
While we cannot exclude that some other PY-NLS proteins,
in addition to FET proteins, might be affected in FTLD-
FUS, our data strongly argue against a general dysfunction
of Trn1 as a primary event in FTLD-FUS inclusion body
formation. In line with that, we did not detect any specific
biochemical alterations of Trn1 such as solubility changes
or presence of abnormal Trn1 species in FTLD-FUS using a
well-established sequential protein extraction protocol, able
to reveal clear solubility changes for FUS, TAF15 and EWS
in FTLD-FUS (this study, [25, 27]). However, our bio-
chemical data are in disagreement with a previous
publication describing a shift towards insolubility for Trn1
in aFTLD-U and NIFID [4]. This discrepancy might be due
to different extraction protocols used, an issue which needs
to be further addressed in future studies.
Fig. 5 Absence of selected
other Trn1 cargos (hnRNP A1,
SAM68 and PABPN1) in
FTLD-FUS. Double-label
immunofluorescence for FUS
(red) and other Trn1 cargos with
PY-NLS (hnRNP A1, SAM68
and PABPN1, respectively,
green) with DAPI staining of
nuclei in the merged images in
FTLD-FUS. FUS-positive
inclusions in FTLD-FUS as
shown here in the dentate gyrus
of aFTLD-U were not labeled
for hnRNP A1 (a), SAM68
(b) and PABPN1 (c). Scale bar
10 lm
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Based on our data we hypothesize an alternate scenario
in which some abnormal posttranslational modifica-
tion(s) that specifically affect FET proteins interferes with
their normal Trn1 binding and dissociation and subse-
quently the proper nucleocytoplasmic transport of these
shuttling proteins and their subcompartmental distribution
in FTLD-FUS. Described posttranslational modifications of
FET proteins include phosphorylation and arginine meth-
ylation and these have been shown to affect the cellular
distribution, RNA/DNA-binding ability, protein–protein
interaction, and protein stability of FET proteins in vitro [1,
2, 12, 30, 34, 35]. Beside changes in solubility of FET
proteins [25, 27, 28], no disease-associated posttransla-
tional changes have yet been reported in FTLD-FUS;
however, this requires more detailed characterization.
Notably, arginine methylation of FUS has been recently
reported to weaken its interaction with Trn1 [8]. Together
with the findings of co-accumulation of Trn1 in inclusions
in FTLD-FUS, it is tempting to speculate that a reduced
methylation status of FET proteins might be present in
FTLD-FUS which would lead to a very tight binding to
Trn1, thus hampering the normal dissociation of the
transport complex resulting in co-accumulation of Trn1
and FET proteins in cytoplasmic and nuclear inclusions.
In summary, we have demonstrated striking differences
in the accumulation of Trn1 in the spectrum of FUS-opa-
thies with consistent Trn1 accumulation in FTLD-FUS but
not in ALS-FUS, thereby providing further strong evidence
for different mechanisms underlying inclusion body for-
mation in FTLD-FUS and ALS-FUS. Notably, despite the
dramatic changes in the subcellular distribution of Trn1 in
FTLD-FUS, alterations of its cargo proteins were found to
be restricted to FET proteins in FTLD-FUS, implying a
specific dysfunction in the interaction between Trn1 and all
FET proteins, most likely by posttranslational modifica-
tions of FET proteins, in the pathogenesis of FTLD-FUS.
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